<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424773</url>
  </required_header>
  <id_info>
    <org_study_id>K101201</org_study_id>
    <nct_id>NCT02424773</nct_id>
  </id_info>
  <brief_title>Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients</brief_title>
  <acronym>RESPIR-OH</acronym>
  <official_title>Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In immunocompromised patients, Acute Respiratory Failure (ARF) is associated with a high
      case-fatality, particularly when invasive Mechanical Ventilation (MV) is required. In the
      most hypoxemic patients, oxygen administration through High Flow Nasal Cannula (HFNC) has
      been reported as an alternative to the venturi mask. The aim of this study is to compare HFNC
      and venturi mask on early respiratory deterioration and patient's comfort in that setting.
      The investigators planned a prospective randomized study in 4 Intensive Care Units (ICUs). As
      respiratory deterioration occurs early after ICU admission, patients are randomized to
      receive two hours of oxygen therapy either through HFNC or venturi mask. The primary endpoint
      is defined as the need for invasive or noninvasive MV in the 2-hour period. Secondary
      endpoints include comfort, dyspnea and thirst.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation failure</measure>
    <time_frame>2 hours</time_frame>
    <description>Oxygenation failure is defined with the need of invasive Mechanical Ventilation or Non invasive ventilation during the two hours study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comfort (0-10 Visual analog Scale)</measure>
    <time_frame>1 hour</time_frame>
    <description>0-10 Visual analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comfort (0-10 Visual analog Scale)</measure>
    <time_frame>2 hours</time_frame>
    <description>0-10 Visual analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea (0-10 Visual analog Scale)</measure>
    <time_frame>1 hour</time_frame>
    <description>0-10 Visual analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea (0-10 Visual analog Scale)</measure>
    <time_frame>2 hour</time_frame>
    <description>0-10 Visual analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thirst (0-10 Visual analog Scale)</measure>
    <time_frame>1 hour</time_frame>
    <description>0-10 Visual analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thirst (0-10 Visual analog Scale)</measure>
    <time_frame>2 hour</time_frame>
    <description>0-10 Visual analog Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Immunocompromised Host</condition>
  <condition>High Flow Oxygen Cannula</condition>
  <arm_group>
    <arm_group_label>Venturi group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Canula (HFNC)</intervention_name>
    <arm_group_label>HFNC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venturi mask</intervention_name>
    <arm_group_label>Venturi group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <arm_group_label>Venturi group</arm_group_label>
    <arm_group_label>HFNC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years.

          -  Admission to ICU for ARF. ARF was defined with the need of oxygen over 6l/min to
             maintain SpO2 over 95% or symptom of respiratory distress (intercostal recession or
             tachypnea &gt;30/min or dyspnea at rest).

          -  Immunosuppression. Immunosuppressed conditions were solid tumor, hematological
             malignancy, steroid treatment or other immunosuppressive treatment, or HIV infection.

        Exclusion Criteria:

          -  Hypercapnia (above 47 mmHg)

          -  Chronic respiratory failure

          -  Previous mechanical ventilation in the days before admission

          -  Need of immediate NIV or intubation

          -  Refusal

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie COURTIAL DESTEMBERT</last_name>
    <role>Study Director</role>
    <affiliation>DRCD APHP Paris</affiliation>
  </overall_official>
  <results_reference>
    <citation>Lemiale V, Mokart D, Mayaux J, Lambert J, Rabbat A, Demoule A, Azoulay E. The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial. Crit Care. 2015 Nov 2;19:380. doi: 10.1186/s13054-015-1097-0.</citation>
    <PMID>26521922</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

